Trial Profile
A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 04 Aug 2021 Primary endpoint (Percentage of CD27+ Switched Memory B Cells at Week 12) has not been met as per results published in the Arthritis and Rheumatology
- 04 Aug 2021 Results published in the Arthritis and Rheumatology
- 07 Nov 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.